SI4143169T1 - Postopki za pripravo inhibitorja kinaze - Google Patents

Postopki za pripravo inhibitorja kinaze

Info

Publication number
SI4143169T1
SI4143169T1 SI202130435T SI202130435T SI4143169T1 SI 4143169 T1 SI4143169 T1 SI 4143169T1 SI 202130435 T SI202130435 T SI 202130435T SI 202130435 T SI202130435 T SI 202130435T SI 4143169 T1 SI4143169 T1 SI 4143169T1
Authority
SI
Slovenia
Prior art keywords
processes
preparation
kinase inhibitor
kinase
inhibitor
Prior art date
Application number
SI202130435T
Other languages
English (en)
Slovenian (sl)
Inventor
Frenel Demorin
Khalid Shah
Sagar Shakya
Yong Wang
Wei Xu
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of SI4143169T1 publication Critical patent/SI4143169T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI202130435T 2020-04-30 2021-04-30 Postopki za pripravo inhibitorja kinaze SI4143169T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017739P 2020-04-30 2020-04-30
EP21727657.5A EP4143169B1 (en) 2020-04-30 2021-04-30 Processes for the preparation of a kinase inhibitor
PCT/US2021/030035 WO2021222673A1 (en) 2020-04-30 2021-04-30 Processes for the preparation of a kinase inhibitor

Publications (1)

Publication Number Publication Date
SI4143169T1 true SI4143169T1 (sl) 2026-07-31

Family

ID=76076455

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202130435T SI4143169T1 (sl) 2020-04-30 2021-04-30 Postopki za pripravo inhibitorja kinaze

Country Status (27)

Country Link
US (1) US12497367B2 (cg-RX-API-DMAC7.html)
EP (1) EP4143169B1 (cg-RX-API-DMAC7.html)
JP (2) JP7728795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005190A (cg-RX-API-DMAC7.html)
CN (2) CN115461328B (cg-RX-API-DMAC7.html)
AU (1) AU2021263474A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176042A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003008A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015205A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220551A (cg-RX-API-DMAC7.html)
DK (1) DK4143169T3 (cg-RX-API-DMAC7.html)
FI (1) FI4143169T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20267875B (cg-RX-API-DMAC7.html)
HR (1) HRP20260608T1 (cg-RX-API-DMAC7.html)
IL (2) IL297684B2 (cg-RX-API-DMAC7.html)
LT (1) LT4143169T (cg-RX-API-DMAC7.html)
MA (1) MA59466B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013528A (cg-RX-API-DMAC7.html)
PE (1) PE20230110A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552821A1 (cg-RX-API-DMAC7.html)
PT (1) PT4143169T (cg-RX-API-DMAC7.html)
RS (1) RS68116B1 (cg-RX-API-DMAC7.html)
SI (1) SI4143169T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600219T1 (cg-RX-API-DMAC7.html)
TW (1) TWI887405B (cg-RX-API-DMAC7.html)
WO (1) WO2021222673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154105A (zh) 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
SMP200900002B (it) 2006-06-12 2010-01-19 Novartis Ag Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide
CN101466672B (zh) 2006-06-12 2012-05-16 诺瓦提斯公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
CA2743416A1 (en) * 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
TW201920110A (zh) * 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2012009722A1 (en) * 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
IL324105A (en) 2025-12-01
CN115461328A (zh) 2022-12-09
JP7728795B2 (ja) 2025-08-25
TW202208335A (zh) 2022-03-01
BR112022021712A2 (pt) 2022-12-06
IL297684A (en) 2022-12-01
MX2022013528A (es) 2022-11-16
JP2025128388A (ja) 2025-09-02
SMT202600219T1 (it) 2026-07-16
AU2021263474A1 (en) 2022-11-17
KR20230005190A (ko) 2023-01-09
PH12022552821A1 (en) 2024-02-12
EP4143169A1 (en) 2023-03-08
IL297684B2 (en) 2026-07-01
US12497367B2 (en) 2025-12-16
HRP20260608T1 (hr) 2026-06-05
DK4143169T3 (en) 2026-06-08
CN121591655A (zh) 2026-03-03
CR20220551A (es) 2022-12-07
LT4143169T (lt) 2026-07-10
EP4143169B1 (en) 2026-04-15
GEP20267875B (en) 2026-03-25
TWI887405B (zh) 2025-06-21
CO2022015205A2 (es) 2022-10-31
PE20230110A1 (es) 2023-01-25
US20230192619A1 (en) 2023-06-22
CN115461328B (zh) 2025-11-07
CA3176042A1 (en) 2021-11-04
FI4143169T3 (fi) 2026-06-08
MA59466B1 (fr) 2026-05-26
PT4143169T (pt) 2026-05-21
RS68116B1 (sr) 2026-06-30
JP2023524692A (ja) 2023-06-13
CL2022003008A1 (es) 2023-06-23
WO2021222673A1 (en) 2021-11-04
IL297684B1 (en) 2026-03-01